Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Hartshead Resources And 2 Other Promising Penny Stocks On The ASX

In This Article:

The Australian stock market has shown resilience, with the ASX200 closing up 0.48% at 8,231 points, driven by gains in the Materials sector and a lift in iron ore prices. For investors looking beyond established giants, penny stocks offer intriguing possibilities despite being an older term for smaller or newer companies. These stocks can present unique opportunities for growth when supported by strong financials and fundamentals, making them worthy of attention as potential hidden gems in the investment landscape.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.77

A$142.2M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.56

A$67.4M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.535

A$331.78M

★★★★★☆

SHAPE Australia (ASX:SHA)

A$2.91

A$239.61M

★★★★★★

Vita Life Sciences (ASX:VLS)

A$1.89

A$108.78M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.96

A$317.49M

★★★★★★

SKS Technologies Group (ASX:SKS)

A$1.59

A$235.35M

★★★★★★

Big River Industries (ASX:BRI)

A$1.285

A$108M

★★★★★☆

Navigator Global Investments (ASX:NGI)

A$1.54

A$747.37M

★★★★★☆

Servcorp (ASX:SRV)

A$4.93

A$482.47M

★★★★☆☆

Click here to see the full list of 1,024 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Hartshead Resources

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Hartshead Resources NL is involved in the exploration and development of oil and gas properties in the United Kingdom, Gabon, and Madagascar, with a market cap of A$16.89 million.

Operations: The company generates revenue of A$4.68 million from its oil and gas development and exploration activities.

Market Cap: A$16.89M

Hartshead Resources NL, with a market cap of A$16.89 million, is pre-revenue and currently unprofitable, yet it has reduced losses over the past five years by 44.5% annually. The company benefits from an experienced management team and board, with average tenures of 3.9 and 6.7 years respectively. Hartshead is debt-free and its short-term assets of A$24.5 million comfortably cover its short-term liabilities of A$3 million, providing a cash runway exceeding three years if cash flow trends persist. However, the stock experiences high volatility compared to most Australian stocks and lacks meaningful revenue streams at present.

ASX:HHR Financial Position Analysis as at Jan 2025
ASX:HHR Financial Position Analysis as at Jan 2025

Immuron

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Immuron Limited is a biopharmaceutical company focused on the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada with a market cap of A$19.71 million.